Regulus slides after hep C contender's results underwhelm investors

Regulus Therapeutics upped the dosage of its microRNA hepatitis C therapy RG-101 in a small study and gathered evidence of a bigger impact on patients' viral loads. But investigators also added new evidence that the treatment was far less durable than the new therapies hitting the marketplace, sending a shiver through the market this morning.

Why crowdfunding will never be a big factor in biotech

LONDON--The Financial Times is trumpeting the Welsh biotech Cell Therapy, which managed to raise a little more than $1 million from a crowdfunding project to back its work on a cell therapy to repair heart damage. That's a record for the U.K. industry.

CrystalGenomics joins Daewoong to commercialize Acelex in South Korea

CrystalGenomics signed a sales and marketing deal with South Korea's Daewoong Pharmaceutical for the commercialization of Acelex (polmacoxib), granting the South Korean firm exclusive rights in country for the osteoarthritis treatment.

U.K. trade & investment chief in India on biotech tour

The head of the U.K.'s Trade & Investment Ministry has begun a three-day visit to India to focus on biotech and health issues, beginning with the Bangalore India Bio, the nation's major biotech conference.

FDA Commissioner Margaret Hamburg to step down

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Sanofi taps Adimab for antibody R&D

Sanofi inked a deal with the antibody discovery experts at Adimab, partnering up to generate a fleet of potential medicines.

Pfizer's still a likely buyer after its $17B 'hors d'oeuvre'

After signing up to acquire Hospira for $17 billion, Pfizer is just getting started, analysts say, pointing to Pfizer's failed quest for AstraZeneca as evidence that the drugmaker is looking for some transformational M&A.

Woodford readies a $300M wager on struggling U.K. biotech sector

LONDON--High-profile British fund manager Neil Woodford rolled out plans to raise about $300 million for an investment trust that will bet heavily on the U.K.'s struggling biotech sector.

Synta cuts another 20% of staff and rallies around its cancer drug

Synta Pharmaceuticals is again slashing its payroll, cutting costs across the board as it presses ahead with ganetespib, a long-delayed cancer treatment.

U.S. Chamber knocks IP laggards India, Indonesia, Thailand and Vietnam in Asia

SINGAPORE--India, Indonesia, Thailand and Vietnam are at the bottom in terms of protections for intellectual property, and much of the rest of Asia is ranked near them in an assessment by a U.S. Chamber of Commerce unit. Singapore was ranked in the top 5 in the Pacific region with Australia, Japan, New Zealand and South Korea close behind.

Activists come for the foundering Aegerion as Denner takes a stake

A syndicate led by activist investor Alex Denner has acquired roughly 5.8% of Aegerion Pharmaceuticals, contending that the struggling biotech's shares are undervalued and requesting a sit-down with management.

Fujifilm's Toyama unit set to publish promising early clinical results in treating Ebola

SINGAPORE--Fujifilm's Toyama Chemical is readying a study for a scientific journal stating that its Avigan (favipiravir) influenza drug has shown promise in treating ebolavirus so far in an early-phase clinical trial in the West African country of Guinea.

Big shot investor plans £100M EU biotech fund, Genmab up on PhII data, J&J inks U.K. RA deal

In this week's EuroBiotech Report, after years of relying heavily on Neil Woodford's checkbook, early-stage British and European biotechs could soon have another big-name investor to tap for cash: Jim Mellon--a man worth around £800 million ($1.2 billion)--is preparing to get deeper into biotech with a £100 million fund. And more.

Roche's Parkinson's failure a blow to researchers; Nexvet pulls off a $40M IPO;

@FierceBiotech: G1 banks $33M to cut in on a blockbuster oncology race. News | Follow @FierceBiotech @JohnCFierce: Look for more M&A ahead: Pfizer beefs up on biosimilars with $15B Hospira deal....

Sanofi's finally going to name a new CEO, chairman says

Sanofi will announce its new chief executive by the end of March, the drugmaker's chairman said, ending months of speculation and reported recruitment failure.

AstraZeneca embraces the biotech lifestyle in a make-or-break year

AstraZeneca's R&D blueprint for 2015 calls for hunkering down on its core pipeline assets and taking a cue from the startup world with the rest, CEO Pascal Soriot said, planning to partner up in hopes of maximizing value.

UPDATED: Pfizer beefs up on biosimilars with $15B Hospira deal

Pfizer CEO Ian Read is dipping into the pharma giant's big reserve of cash to gobble up Hospira, one of the pioneers in the move to develop biosimilars of blockbuster biologics.

Armetheon raises $24M to get its anticoagulant into Phase III

Menlo Park, CA's Armetheon raised a $24.3 million B round to support work on a new oral blood thinner the biotech believes can fill a hole in the blockbuster anticoagulant market.

FDA chief Hamburg is stepping down. Is Califf the next commissioner?

FDA Commissioner Margaret Hamburg is set to step down, according to Reuters, weeks after appointing a deputy many believe to be her hand-picked successor.

Place your bets: TCM, biotech asset reshuffles highlight Chinese deals

SINGAPORE--Harbin Gloria Pharmaceuticals will pay RMB 2.39 billion to acquire an 85% stake in Shanxi Powerdone Pharmaceutics, one of two domestic deals in late January involving mainland firms reshuffling biotech assets and traditional Chinese medicines.